KIR2DL4 (CD158d) polymorphisms and susceptibility to multiple sclerosis

Journal of Neuroimmunology

Volumn 210, Issue 1-2, 2009, Pages 113-115

  Goris, An ^a   Dobosi, Rita ^a   Boonen, Steven ^b   Nagels, Guy ^c   Dubois, Bénédicte ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c National MS Centre   (Belgium)

Author keywords

Association; Autoimmunity; Genetics; KIR2DL4; Multiple sclerosis; Natural killer cells

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MEMBRANE PROTEIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOREGULATION; KIR2DL4 GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIGENS, CD56; CELL MEMBRANE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RECEPTORS, KIR2DL4; YOUNG ADULT;

EID: 67349115546     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.03.001     Document Type: Article

References (15)

1. Airas L., Saraste M., Rinta S., Elovaara I., Huang Y.H., and WIendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin. Exp. Immunol. Finnish Multiple Sclerosis and Pregnancy Group 151 (2008) 235-243
2. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., McFarland H., Henkart P.A., and Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5941-5946
3. De Jager P.L., Rossin E., Pyne S., Tamayo P., Ottoboni L., Viglietta V., Weiner M., Soler D., Izmailova E., Faron-Yowe L., O'Brien C., Freeman S., Granados S., Parker A., Roubenoff R., Mesirov J.P., Khoury S.J., Hafler D.A., and Weiner H.L. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain 131 (2008) 1701-1711
4. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 25 (2003) 115-221
5. Goodridge J.P., Witt C.S., Christiansen F.T., and Warren H.S. KIR2DL4 (CD158d) genotype influences expression and function in NK cells. J. Immunol. 171 (2003) 1768-1774
6. Goodridge J.P., Lathbury L.J., Steiner N.K., Shulse C.N., Pullikotil P., Seidah N.G., Hurley C.K., Christiansen F.T., and Witt C.S. Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells. Eur. J. Immunol. 37 (2007) 199-211
7. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., Caillier S.J., Ban M., Goris A., Barcellos L.F., Lincoln R., McCauley J.L., Sawcer S.J., Compston D.A., Dubois B., Hauser S.L., Garcia-Blanco M.A., Pericak-Vance M.A., and Haines J.L. Multiple Sclerosis Genetics Group. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39 (2007) 1083-1091
8. International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357 (2007) 851-862
9. International Multiple Sclerosis Genetics Consortium. Refining novel associations in multiple sclerosis. Lancet. Neurol. 7 (2008) 567-569
10. International Multiple Sclerosis Genetics Consortium. The expanding genetic overlap between multiple sclerosis and type 1 diabetes. Genes Immun. 10 (2008) 11-14
11. Lundmark F., Duvefelt K., Iacobaeus E Kockum I., Wallström E., Khademi M., Oturai A., Ryder L.P., Saarela J., Harbo H.F., Celius E.G., Salter H., Olsson T., and Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39 (2007) 1108-1113
12. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sørensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sá M., Salemi G., Savettieri G., Hillert J., and Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64 (2005) 1144_1151
13. Saraste M., Irjala H., and Airas L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci. 28 (2007) 121-126
14. Segal B.M. The role of natural killer cells in curbing neuroinflammation. J. Neuroimmunol. 191 (2007) 2-7
15. Witt C.S., Martin A., and Christiansen F.T. Detection of KIR2DL4 alleles by sequencing and SSCP reveals a common allele with a shortened cytoplasmic tail. Tissue Antigens 56 (2000) 248-257